Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)
Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kuemmel S, Rhiem K, Warm M, Fasching P, Just M, Hanusch C, Hackmann J, Blohmer JU, Furlanetto J, Nekljudova V, Von Minckwitz G, Loibl S (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Publisher: OXFORD UNIV PRESS
City/Town: OXFORD
Pages Range: 60-60
Conference Proceedings Title: ANNALS OF ONCOLOGY
Event location: Munich
DOI: 10.1093/annonc/mdy270.185
Authors with CRIS profile
Involved external institutions
HELIOS Kliniken
Germany (DE)
Krankenhaus Köln-Holweide
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Marien-Krankenhaus
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universitätsklinikum Leipzig
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Krankenhaus Jerusalem
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
St. Barbara-Klinik Hamm
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Elisabeth-Krankenhaus Essen
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Germany (DE)
Krankenhaus Köln-Holweide
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Marien-Krankenhaus
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universitätsklinikum Leipzig
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Krankenhaus Jerusalem
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
St. Barbara-Klinik Hamm
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Elisabeth-Krankenhaus Essen
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
How to cite
APA:
Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C.,... Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). In ANNALS OF ONCOLOGY (pp. 60-60). Munich, DE: OXFORD: OXFORD UNIV PRESS.
MLA:
Untch, M., et al. "Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018. 60-60.
BibTeX: Download